In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Emilie MallecotAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat-Claude Bernard, Laboratoire de Bactériologie, Paris, France.ORCID 0009-0008-0620-9530 Valentine BertiAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat-Claude Bernard, Laboratoire de Bactériologie, Paris, France.
Marie PetitjeanAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat-Claude Bernard, Laboratoire de Bactériologie, Paris, France.
Julie MeyerUniversité Sorbonne Paris Nord et Université Paris Cité, INSERM, IAME, Paris, France.
Signara GueyeAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat-Claude Bernard, Laboratoire de Bactériologie, Paris, France.
Thibaut Morel-JournelUniversité Sorbonne Paris Nord et Université Paris Cité, INSERM, IAME, Paris, France.ORCID 0000-0002-9124-2894 Sarah TimsitAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat-Claude Bernard, Laboratoire de Bactériologie, Paris, France.ORCID 0009-0003-3508-4558 Olivier ClermontUniversité Sorbonne Paris Nord et Université Paris Cité, INSERM, IAME, Paris, France.
Laurent PoirelFaculty of Science and Medicine, Medical and Molecular Microbiology, University of Fribourg, Fribourg, Switzerland.ORCID 0000-0001-5160-5286 Erick Denamur *Université Sorbonne Paris Nord et Université Paris Cité, INSERM, IAME, Paris, France.ORCID 0000-0002-7860-1717 Guilhem Royer *Département de Prévention, Diagnostic et Traitement des Infections, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Créteil, France.ORCID 0000-0001-9092-8336 Laurence Armand-LefevreAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat-Claude Bernard, Laboratoire de Bactériologie, Paris, France.ORCID 0000-0002-2013-3252 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Cefiderocol (FDC) is a new siderophore-conjugated cephalosporin that enters the periplasm
Indexed as
Anti-Bacterial AgentsCephalosporinsEscherichia coliIronbeta-LactamasesCefiderocolDrug Resistance, BacterialEscherichia coli ProteinsMicrobial Sensitivity TestsOperonSiderophoresVirulenceAnti-Bacterial Agentsbeta-LactamasesCefiderocolCephalosporinsEscherichia coli ProteinsIronSiderophorescefiderocolEnterobacteralesEscherichia coliiron uptake systemNDM
Identifiers
PMID42429791
PMCPMC13436293
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390